市場調査レポート

商品コード

342571

心房細動 (AF) の予測：主要19市場

Epiomic Epidemiology Series: Atrial Fibrillation Forecast in 19 Major Markets 2020-2030

出版日: 2020年03月20日 | 発行:

Black Swan Analysis | ページ情報: 英文 76 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 5,800 778,882円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Site License/Up to 5 Users)

USD 8,700 1,168,323円

レポートPDFを同じ国内の同じ事業所内の5名迄にて共有ご利用頂けるライセンスです。ご利用人数の制限はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Corporate License)

USD 10,400 1,396,616円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=134.29円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

心房細動 (AF) は、上室性不整脈の最も一般的なタイプです。異常な電気信号が心房に送られると、心房細動 (AF) が引き起こされます。

当レポートでは、主要19市場 (米国、カナダ、フランス、ドイツ、イタリア、スペイン、英国、ポーランド、オランダ、ロシア、トルコ、日本、中国、韓国、インド、オーストラリア、ブラジル、メキシコ、アルゼンチン) における心房細動 (AF) の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、疾患の概要、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

図表

イントロダクション

病因

危険因子と予防

疾患の診断

変異：地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/特徴

患者数を定量化する手法

心房細動 (AF) の最大有病者数

心房細動 (AF) 患者の特徴

インターベンション治療
心房細動 (AF) 患者の併存疾患

略語

その他のサービス・ソリューション

レポート・出版物
オンライン疫学データベース
オンライン薬価データベース

参考文献

付録

図表

LIST OF TABLES AND FIGURES

Table 1. Prevalence of AF, total (000s)
Table 2. Prevalence of AF, males (000s)
Table 3. Prevalence of AF, females (000s)
Table 4. Patients with AF by classification according to duration of episode, total (000s)
Table 5. Patients with new-onset AF, total (000s)
Table 6. Patients with valvular vs. non-valvular AF, total (000s)
Table 7. AF patients with a history of catheter ablation, total (000s)
Table 8. AF patients on anti-arrhythmic therapy, total (000s)
Table 9. AF patients with an established rhythm control strategy, total (000s)
Table 10. AF patients with a pacemaker / ICD implant, total (000s)
Table 11. AF patients on vitamin K antagonist therapy, total (000s)
Table 12. AF patients on anti-platelet therapy, total (000s)
Table 13. AF patients with a history of stroke, total (000s)
Table 14. Patients with atrial fibrillation by 5-year incidence of stroke event, total (000s)
Table 15. AF patients with coronary artery disease, total (000s)
Table 16. AF patients with chronic heart failure, total (000s)
Table 17. AF patients with peripheral artery disease, total (000s)
Table 18. AF patients with a history of myocardial infarction, total (000s)
Table 19. AF patients with left ventricular hypertrophy, total (000s)
Table 20. AF patients with diabetes, total (000s)
Table 21. AF patients with hypertension, total (000s)
Table 22. AF patients with COPD, total (000s)
Table 23. AF patients with rheumatic heart disease, total (000s)
Table 24. AF patients with valvular artery disease, total (000s)
Table 25. Abbreviations and acronyms used in the report
Table 26. USA prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 27. USA prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 28. Canada prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 29. Canada prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 30. France prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 31. France prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 32. Germany prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 33. Germany prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 34. Italy prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 35. Italy prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 36. Spain prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 37. Spain prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 38. UK prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 39. UK prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 40. Poland prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 41. Poland prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 42. Netherlands prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 43. Netherlands prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 44. Russia prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 45. Russia prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 46. Turkey prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 47. Turkey prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 48. Japan prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 49. Japan prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 50. China prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 51. China prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 52. South Korea prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 53. South Korea prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 54. India prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 55. India prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 56. Australia prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 57. Australia prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 58. Brazil prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 59. Brazil prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 60. Mexico prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 61. Mexico prevalence of atrial fibrillation by 5-yr age cohort, females (000s)
Table 62. Argentina prevalence of atrial fibrillation by 5-yr age cohort, males (000s)
Table 63. Argentina prevalence of atrial fibrillation by 5-yr age cohort, females (000s)

Product Code: ATFB0020820

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Atrial Fibrillation in 19 Major Markets.

Atrial Fibrillation (AF) is the most prevalent type of supraventricular arrhythmia. AF occurs when abnormal electric signals are sent to the atria, which cause them to contract quickly and irregularly. For many patients, the condition is largely asymptomatic, however when symptoms become bothersome and frequent, intervention is required to restore normal rhythm.

This report provides the current prevalent population for AF across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the classification and patient treatment options for AF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main patient features and co-morbidities of AF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AF include:

Hypertension
CHF/CAD and other structural cardiac diseases
Diabetes
Mitral stenosis / other valvular disorders
COPD
Stroke
Rheumatic heart disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.